Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
E5555 + diltiazem
- Development stage
- Phase 1
- Lead developer
- Eisai
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
E5555 is an investigational drug (not described in the provided sources; based on external knowledge it is a selective protease-activated receptor-1 [PAR-1] antagonist developed for cardiovascular indications). Diltiazem is a non-dihydropyridine calcium channel blocker used to treat hypertension (high blood pressure), angina (chest pain), and certain heart arrhythmias. It works by inhibiting the influx of calcium ions into cardiac and vascular smooth muscle cells during depolarization. This action relaxes blood vessels and reduces the workload on the heart while increasing coronary blood flow. Diltiazem is approved for use as an antihypertensive agent and antianginal agent[1][2][3][4][5][6].
- Brand names
- Dilacor XRDilt-CDDiltia XTDilt-XRDiltzacTaztia XT
- Other names
- benzothiazepine derivative (for diltiazem)
02
Targets
F2R (Protease-activated receptor 1)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)
Beyond the preview
Go deeper on E5555 + diltiazem.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on E5555 + diltiazem.